Scholarlink

The management of high-risk and locally advanced prostate cancer (PCa) is one of the most compelling contemporary challenges. These patients have an increased risk of prostate-specific antigen (PSA) failure, need additional therapy, exhibit metastatic progression and suffer cancer-related death following primary treatment. Discrimination of patients with very poor outcomes remains challenging. No consensus exists on the definition of high-risk and locally advanced PCa, resulting in heterogeneous oncological outcomes of this population. Moreover, the optimal treatment strategy for these patients remains unclear. Eventually, most high-risk and locally advanced PCa patients will need multimodality treatment to attain cure (surgery ± radiotherapy (RT) ± systemic therapy).

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Management of High-Risk and Locally Advanced Disease

  • 章节

  • 发表日期：

    2025年

查看全文
  • Gaëtan Devos,
  • Charlien Berghen,
  • Lisa Moris,
  • Wout Devlies,
  • Daimantas Milonas,
  • Thomas Van den Broeck,
  • Sander Jentjens,
  • Gert De Meerleer,
  • Steven Joniau

摘要

The management of high-risk and locally advanced prostate cancer (PCa) is one of the most compelling contemporary challenges. These patients have an increased risk of prostate-specific antigen (PSA) failure, need additional therapy, exhibit metastatic progression and suffer cancer-related death following primary treatment. Discrimination of patients with very poor outcomes remains challenging. No consensus exists on the definition of high-risk and locally advanced PCa, resulting in heterogeneous oncological outcomes of this population. Moreover, the optimal treatment strategy for these patients remains unclear. Eventually, most high-risk and locally advanced PCa patients will need multimodality treatment to attain cure (surgery ± radiotherapy (RT) ± systemic therapy).